Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back

YEAR IN REVIEW

YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST: CLINICAL CARDIOLOGY

334 - PERI-OPERATIVE MANAGEMENT CONTROVERSIES

Saturday, October 26, 2024
11:00 AM – 11:15 AM PT
Room: 211
• 72 yr. man with FC 3 claudication with 6.5 cm AAA, Remote PCI 10 yrs ago & stable IHD, EF 60%, on ASA, ACEI and statin
I. Risk stratification & stress imaging - “exercise in futility”?
II. Approach to pre-op cardiac medications
a) Hypotensive vs hypertensive avoidance strategy
b) Routine “prophylactic” B Blocker-yes or no?
c) Chronic AF on DOAC
d) GLP-1A & SGLT2i
III. Role of cardiac biomarkers (NT-BNP/TnT) pre/post-op
IV. Post-operative AF with RVR and chest pain, TnT 500 with ischemic ECG-cardiac cath mandatory vs. non-invasive imaging
Disclosure(s):
Emilie P. Belley-Cote, MD: Abbott: unrestricted grant (Ongoing); Bayer: Unrestricted investigator grant (Terminated, December 31, 2023); BMS-Pfizer: unrestricted grant (Terminated, December 31, 2022); Roche Diagnositcs: unrestricted grant (Terminated, December 31, 2023); Trimedic Therapeutics: consulting (Terminated, February 13, 2023)